{
    "clinical_study": {
        "@rank": "134338", 
        "acronym": "SAIL", 
        "arm_group": {
            "arm_group_label": "Rapamycin and Hydroxychloroquine", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will take sirolimus at an initial dose of 2mg followed by dose adjustment to keep sirolimus trough levels between 5-15ng/ml consistent with the effective dose in the MILES trial.  In addition to sirolimus subjects will receive hydroxychloroquine at 200 mg daily or twice a day for 6 months, depending on time of enrollment into the study, following a standard phase I dose escalation."
        }, 
        "brief_summary": {
            "textblock": "Specific Aim 1: To investigate whether, in Lymphangioleiomyomatosis (LAM) patients, the\n      combination of sirolimus and hydroxychloroquine is safe and well tolerated\n\n      Specific Aim 2:  To investigate whether, in LAM patients, 6 months of combination therapy\n      with sirolimus and hydroxychloroquine results in improvement of indicators of disease, and\n      whether the gains are sustained after stopping therapy.\n\n      Specific Aim 3:  To investigate the potential role of a LAM-specific peripheral blood\n      signature to predict rates of disease progression and determine responsiveness to\n      combination therapy.\n\n      This will be a phase I dose escalation study of the combination of sirolimus (2 mg adjusted\n      to keep trough levels between 5-15 ng/ml) and hydroxychloroquine (200 mg or 400 mg) taken\n      orally daily.  Up to 18 adult women with LAM will be enrolled."
        }, 
        "brief_title": "Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Lymphangioleiomyomatosis", 
        "condition_browse": {
            "mesh_term": "Lymphangioleiomyomatosis"
        }, 
        "detailed_description": {
            "textblock": "This will be a phase I dose escalation study of the combination of sirolimus (2 mg adjusted\n      to keep trough levels between 5-15 ng/ml) and hydroxychloroquine (200 mg or 400 mg) taken\n      orally daily for 6 months.  The study is to be conducted at 2 sites.  Up to 18 adult women\n      with LAM will be enrolled, and each recruiting site will recruit between 8-12 subjects. The\n      protocol will use the following eligibility criteria."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female age 18 or older\n\n          -  Ability to give informed consent\n\n          -  Diagnosis of LAM as defined as typical cystic change on CT plus:\n\n               -  biopsy or cytology of any tissue demonstrating LAM\n\n               -  angiomyolipoma, chylothorax, lymphangioleiomyoma, or tuberous sclerosis\n\n               -  serum VEGFD greater or equal to 800pg/ml\n\n          -  Post-bronchodilator FEV1 equal or less than 80% of predicted or DLCO equal equal or\n             less than 70% of predicted, or RV > 120% of predicted at baseline\n\n          -  Women of childbearing potential must agree to use 2 forms of barrier contraception\n             during and for 8 weeks after the last dose of medication.\n\n        Exclusion Criteria:\n\n          -  History of intolerance of mTOR inhibitors\n\n          -  History of intolerance to hydroxychloroquine\n\n          -  History of severe psoriasis\n\n          -  History of porphyria cutanea tarda\n\n          -  Uncontrolled intercurrent illness\n\n          -  Pregnant, breast feeding, or plan to become pregnant in the next year\n\n          -  Inadequate contraception\n\n          -  Significant hematological or hepatic abnormalities\n\n          -  Use of an investigational drug within 30 days of study start\n\n          -  Inability to attend scheduled clinic visits\n\n          -  Inability to perform PFTs\n\n          -  Creatinine > 2.5mg/dL\n\n          -  Recent pneumothorax within 8 weeks of screening\n\n          -  History of malignancy in the last 2 years other than basal cell skin cancer\n\n          -  Use of estrogen containing medication within 30 days of screening\n\n          -  Abnormal G6PD levels at baseline\n\n          -  Preexisting maculopathy or retinopathy\n\n          -  Preexisting myopathy\n\n          -  Currently taking doxycycline, metformin, lupron, simvastatin\n\n          -  Unable to undergo CT or MRI\n\n          -  History of seizure within last year\n\n          -  Hepatitis B, C, HIV positive serology\n\n          -  Use of alternative medical therapies for LAM for at least 6 weeks prior to study\n             participation\n\n          -  History of myocardial infarct, angina, or stroke related to atherosclerosis\n\n          -  History of cardiomyopathy\n\n          -  Previous lung transplant\n\n          -  Surgery (involving entry into a body cavity or requiring 3 or more stitches) within 2\n             months of initiation of study drug\n\n          -  Uncontrolled cholesterol > 350mg/dL, triglycerides > 400mg/dL"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01687179", 
            "org_study_id": "SAIL-1100"
        }, 
        "intervention": {
            "arm_group_label": "Rapamycin and Hydroxychloroquine", 
            "description": "This will be a phase I dose escalation study of the combination of sirolimus (2 mg adjusted to keep trough levels between 5-15 ng/ml) and hydroxychloroquine (200 mg or 400 mg) taken orally daily.", 
            "intervention_name": "sirolimus and hydroxychloroquine", 
            "intervention_type": "Drug", 
            "other_name": "sirolimus(rapamune), hydroxychloroquine (plaquenil)"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Hydroxychloroquine", 
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "LAM", 
            "TSC", 
            "lymphangioleiomyomatosis"
        ], 
        "lastchanged_date": "July 30, 2013", 
        "location": {
            "contact": {
                "email": "epeters2@partners.org", 
                "last_name": "Betsy Peters, RN", 
                "phone": "617-525-9331"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02120"
                }, 
                "name": "Brigham and Women's Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Targeting Autophagy for the Treatment of TSC and LAM: a Phase I Trial of Hydroxychloroquine and Sirolimus", 
        "overall_contact": {
            "email": "epeters2@partners.org", 
            "last_name": "Betsy M Peters, BSN, RN", 
            "phone": "617-525-9331"
        }, 
        "overall_contact_backup": {
            "email": "ehenske@partners.org", 
            "last_name": "Elizabeth P Henske, MD", 
            "phone": "617-355-9049"
        }, 
        "overall_official": [
            {
                "affiliation": "Brigham and Women's Hospital", 
                "last_name": "Elizabeth P Henske, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "last_name": "Joel Moss, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will conduct a two-center phase I trial of sirolimus (mTOR inhibitor) in combination with hydroxychloroquine (autophagy inhibitor 200-400mg) administered daily for 24 weeks.  Eligible subjects will receive sirolimus at an initial dose of 2mg followed by dose adjustment to keep sirolimus trough levels between 5-15ng/ml consistent with the effective dose in the MILES trial.  In addition to sirolimus subjects will receive hydroxychloroquine at 200 mg daily or twice a day for 6 months, depending on time of enrollment into the study, following a standard phase I dose escalation design. All adverse events will be captured.", 
            "measure": "safety of everolimus and hydroxychloroquine", 
            "safety_issue": "Yes", 
            "time_frame": "4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01687179"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Brigham and Women's Hospital", 
            "investigator_full_name": "Elizabeth Henske", 
            "investigator_title": "Overall Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Brigham and Women's Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Brigham and Women's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}